| abstract |
Described herein are compounds, compositions, and methods for diagnosing and / or monitoring pathogenic diseases using positron emission tomography. In addition, the formula B-L-P (wherein B is a radical of a target drug selected from a vitamin receptor binding ligand (eg, folic acid), a PSMA binding ligand, or a PSMA inhibitor, and L is an aspartic acid, lysine Or a divalent linker containing arginine, where P is a radical of an imaging agent or radiotherapeutic agent such as a radionuclide or a radionuclide-containing group, or a radical of a compound capable of binding to a radionuclide such as a metal chelate group Is described). |